Obsessional-Compulsive Disorder (OCD) can involve poor insight, which may complicate the differential diagnosis of schizophrenia. Otherwise, few cases may associate both diagnosis highlighting the need for a clearer understanding of the factors of their coexistence.

Understand the factors that contribute to the comorbidity between OCD and schizophrenia.

Our study employed a case report approach that describes a patient admitted in our psychiatric unit. Data were collected through clinical interviews, personal and family medical history. We also conducted a literature research focusing on articles published between 2000 and 2023 in PubMed using the keywords « OCD », « schizophrenia » and « comorbidity ».

The case concerns Mr. N, a 43-year-old man with no significant medical or psychiatric history and no reported substance use behaviors, who was admitted to our psychiatric unit. He was diagnosed with both OCD and schizophrenia. The therapeutic evaluation revealed that Mr. N was initially prescribed anxiolytics, with a second-generation antipsychotic subsequently added. Some researches suggests that second-generation antipsychotics may induce obsessive-compulsive symptoms which could explain the coexistence of the two diagnosis in Mr N. Additionally, other studies have indicated that genetic factors can predispose individuals to both conditions whereas our patient does not have any notable family history of psychiatric disorders. Finally, literature says that neurobiological factors particularly shared dopaminergic and serotonergic pathways may provide an explanation for the comorbidity of OCD and Schizophrenia.

The comorbidity of OCD and schizophrenia may be explained by several factors, making diagnosis and treatment challenging.

None Declared

There is a greater inequality in employment and underemployment among adults with Autism Spectrum Disorder (ASD) compared to their peers. Aspects such as sustained eye contact, interpreting non-verbal cues, understanding non-literal language, exhibiting cognitive inflexibility, and limitations in interpreting others’ perspectives impact their communication. Due to these difficulties, they are often subject to social embarrassment, isolation, and insecurity when initiating conversations. Considering that contemporary interactions have intensified through social media, these networks can be a facilitator of social inclusion, especially as they are digital environments—structured, free from unexpected stimuli, offering additional processing time, and without the need to interpret prosody and intonation. In this context, to understand its impact in the workplace for this population, one of the factors to consider is the self-esteem of these individuals within the workplace, given that self-esteem is a fundamental indicator of self-worth and self-acceptance, impacting mental health.

To verify the correlation between social media use and self-esteem in adults with ASD in their workplace.

This is a prospective, qualitative-quantitative study based on the Ethics Committee for Research number 65890317.9.0000.0065. Data were collected via an electronic form. Questionnaires: personal/social questions prepared by the authors; adapted protocols: Rosenberg Self-Esteem Scale and Facebook Intensity Scale.

A total of 132 adults with self-reported ASD, 68% of whom had ASD with comorbidities. Regarding gender and sexual orientation, 66% were cisgender and heterosexual women, and 62% were cisgender and heterosexual men. Concerning remuneration and education, 44.7% had completed higher education, earning between two to three thousand reais per month. Additionally, 61.4% reported not having inclusive strategies in their workplace. The overall correlation between self-esteem and social media use at work showed that 65.9% use social media moderately, of which 12.9%, 18.9%, and 34.1% have low, high, and medium self-esteem, respectively. Correlating personal/social questions with self-esteem, 34.8% never feel comfortable with group conversations, of which 11.4% have low self-esteem (p-value 0.008), 48.5% feel distressed at work (p-value 0.06), 62.9% are excessively concerned about work (p-value 0.02), and 49.2% find it difficult to assert themselves at work (p-value 0.02). (Image 1)

Image 1:

This study did not statistically demonstrate a correlation between social media use and self-esteem in the workplace. However, the challenges encountered in the workplace, such as the lack of inclusive strategies, social difficulties that generate fear, distress, and worry, corroborate the literature regarding the vulnerability this population is exposed to.

None Declared

People with psychosis present a significantly higher premature death, leading to a reduction of life expectancy of up to 15-20 years.

To a high extent, this premature mortality is due to a higher incidence of common physical conditions, appearing earlier than in the general population. Traditionally, the focus has been put on the cardiovascular diseases. However, more recently, there ir mounting evidence of the contribution of other conditions to this premature mortality, such as repiratory (e.g.: chronic obstructive pulmonary disease) and liver (MAFLD) conditions.

We are presenting results from PAFIP and ITPCan early intervention programs (Cantabria, Spain), regarding the early impact of psychosis on physical health, observing early alterations at the organic level (e.g.: liver, lung), which precede the development of chronic organic pathology causing premature mortality in the general population.

None Declared

Lumateperone, an atypical antipsychotic drug, has a dual mechanism of action by combination of activity at central serotonin (5-HT2A) and dopamine (D2) receptors.

This subgroup analysis of an Indian Phase 3 study was conducted to evaluate the efficacy and safety of Lumateperone 42mg compared to Quetiapine 300mg in treatment of Bipolar II depression when stratified based on disease duration.

The phase-III, randomized, multi-centric, assessor-blind, parallel-group, active-controlled, comparative, non-inferiority study included patients with Bipolar II depression with moderate severity having a Montgomery-Asberg depression rating scale (MADRS) score ≥20 and Clinical global impression–bipolar version–severity (CGI-BP-S) score ≥4. The study was conducted after receiving regulatory and ethics committee approvals. The patients were randomized (1:1) to either receive Lumateperone 42mg [Test] or Quetiapine 300mg [Comparator] for 6 weeks. The patients were stratified based on disease duration: Subgroup 1 [S1]: ≤6 months and Subgroup 2 [S2]: >6 months. For efficacy outcomes MADRS score, CGI-BP-S (total score, depression subscore and overall bipolar illness subscore), and Quality of life enjoyment and satisfaction-short form questionnaire (Q-LES-Q-SF) score were evaluated and for safety outcomes treatment emergent adverse events (TEAEs) were assessed. [Clinical trial registration: CTRI/2023/10/058583]

This subgroup analysis included 462 patients, out of which 118 in S1[Test=62; Comparator=56] and 344 in S2[Test=169; Comparator=175]. The baseline demographic characteristics were comparable in between treatment arms across subgroups. The primary endpoint of reduction in MADRS score from baseline to Day 42 in Test arm was non-inferior to Comparator arm in both subgroups [Figure 1] as the upper 95% CI was below the pre-defined margin of 3.0. The reduction of CGI-BP-S (total score, depression subscore and overall bipolar illness subscore) from Day 14 to Day 42 were comparable in both Test and Comparator arms in both subgroups. The improvement in Q-LES-Q-SF score from baseline to Day 42 were comparable in both Test and Comparator arms in both subgroups. The incidence of TEAEs were similar in both treatment arms [S1: Test=30.6% and Comparator=30.4%; S2: Test=36.1% and Comparator=37.1%] and no serious adverse events were reported.

Image 1:

This subgroup analysis demonstrated that Lumateperone 42mg is non-inferior to Quetiapine 300mg in treatment of Bipolar II depression as assessed via MADRS score from baseline to Day 42, irrespective of chronicity of the disease and both treatments were found to be well tolerated. Hence, Lumateperone can be considered as valuable treatment option in management of Bipolar II depression.

A. Dharmadhikari: None Declared, P. Chaurasia: None Declared, Y. Patel: None Declared, D. Choudhary: None Declared, P. Dasud: None Declared, M. Bhirud: None Declared, P. Meena: None Declared, F. Shah: None Declared, G. Ganesan: None Declared, B. P. Rathour: None Declared, K. Mistry: None Declared, M. Dutta: None Declared, A. Ramaraju: None Declared, S. Mangalwedhe: None Declared, S. G. Goyal: None Declared, G. Kulkarni: None Declared, A. Mukhopadhyay: None Declared, P. Chaudhary: None Declared, G. T. Harsha: None Declared, M. Parikh: None Declared, S. Dey: None Declared, S. Sarkhel: None Declared, N. Jyothi: None Declared, A. Kumar: None Declared, N. Sooch: None Declared, A. Shetty Employee of: Sun Pharma, S. Saha Employee of: Sun Pharma, P. Devkare Employee of: Sun Pharma, A. Shetty Employee of: Sun Pharma, D. Patil Employee of: Sun Pharma, P. Ghadge Employee of: Sun Pharma, A. Mane Employee of: Sun Pharma, S. Mehta Employee of: Sun Pharma.

Athletes with physical impairments may experience symptoms of depression and anxiety. At all stages of sports training, it is necessary to consider athletes’ mental state depending on the functional ability – class of a para table tennis player (Rice et al. 2016, Hamer et al. 2008).

This study examines features of psychological training for the Russian national para table tennis team (class 1-10), bearing in mind function classes, mental health, and sports achievements of each team member.

Participants from 2 groups of national para table tennis players (class 1-10) who were training for the 2020 Tokyo Paralympics were analyzed. Group 1 (n=5, 2 males, 3 females) consisted of athletes classified within classes 6-10 (players who compete standing). Group 2 (n=5, 3 males, 2 females) consisted of athletes classified within classes 1-5 (players that compete in a wheelchair). Participants had no mental health complaints at the moment of the study and took part in the process voluntarily. Within these groups, 8 para table tennis players participated in the Tokyo Paralympics and won 5 medals of different merits.

Stages of the study:

Stage 1: developing a differentiated training approach, assessing individual value differences (Schwartz Value Survey, SVS), measuring the quality of life (SF-36), and designing a tailored psychological training approach for each Group.

Stage 2: psychological skills training, quality of life assessment (SF-36), and evaluation of the results of the self-report questionnaire (psycho-emotional state, level of motivation, and satisfaction) right after the end of the Games.

The most significant values in Group 1 are the following: security, conformity, benevolence, self-direction, and achievement. Less pronounced values are the following: power and stimulation (fig. 1). Significant values in group 2 are security, universalism, benevolence, self-direction, and conformity. Virtually not pronounced values are hedonism and power. (fig. 2).

The preparation strategy for Group 1 should focus on adaptive coping strategies (active attitude, emotional support, instrumental support, positive reinterpretation). Group 2 should focus more on social support and foster communication with coaches and teammates.

Quality of life measurement (SF-36) and analysis of the self-report questionnaire show the reduction of the anxiety level and demonstrate a steady increase in the level of motivation, sense of fulfillment, and satisfaction with the achieved results. The result of dynamic observation indicates improvement in quality of life.

Image 1:

Image 2:

Psychological methods used in complex (integrated, comprehensive) training correlate positively with athletes’ performance and beneficially affect their psycho-emotional state. Functional class plays a significant role in choosing psychological methods for coaching para table tennis players and finding an appropriate way to interact with the national team.

None Declared

There are conflicting and inconclusive results regarding suicidality in patients with obsessive-compulsive disorder (OCD).

To describe the different psychopathological aspects of suicidality (suicidal ideation, suicide attempts, completed suicide, family history, etc.) in OCD.

In this case-control study we compared 114 patients with OCD and 127 controls (no OCD general hospital inpatients). The psychopathological aspects of suicidality were obtained through a 24 questions specific suicidality inventory (DETEC-S). Other instruments/data (Beck Depression and Anxiety Inventories, family history of psychiatric disorders, symptom severity scale, and psychiatric comorbidities) will be described in another study.

Patients with OCD reported: less will to live (p=0.005); greater will to die (p<0.001); more reasons to die (p=0.022); greater lifetime history of suicidal ideation (SI) (p<0.001); accept the idea of dying (p<0.001); admit death as an escape from problems (p<0.001); suicidal plan in the past (p=0.019); admit courage and ability to commit suicide (p=0.003); no organization for the afterlife (p=0.021); have already talked to other people about SI (p<0.001); access to a lethal method (p=0.047); higher rates of family members, close people or friends who have already attempted suicide (p=0.008). They did not differ from the controls: would save themselves in case of an accident; current intention to commit suicide; able to control suicidal desire; would not commit suicide because of family, friends or religion; absence of current suicidal plan; suicidal desire or plan in the near future; writing a suicide note; prevalence of lifetime suicide attemp (SA); when they had SA, there was no need for medical care; and suicide success rates of family members, close people or friends. There was no significant difference in the total DETECT-S score (p=0.086). There was a moderate and direct correlation of suicidality scores with: the current severity of OCD and (r=0.32; p=0.001), especially at the expense of the severity of compulsions (r=0.35; p<0.001); and with the severity of depressive symptoms (r=0.43; p<0.001); average rate of lifetime improvement of symptoms (r=0.36; p=0.007). We found a moderate and indirect correlation with total quality of life scores (r=-0.47; p<0.001), especially at the expense of aspects related to the physical (r=-0.47), psychological (-0.47) and environmental (r=-0.42) domains (all with p<0.001).

Suicidality appears to be markedly present in patients with OCD (of the 24 psychopathological aspects of the DETECT-S questionnaire, patients had higher scores in 13 items) even when compared to patients admitted to a general hospital. A detailed approach to suicidality in patients with OCD may help in therapeutic planning and reduce patient suffering.

None Declared

The rare epileptic seizure syndrome nodding is endemic among African adolescents. While the etiology remains poorly understood, its mechanistic hypothesis suggests a neuroinflammatory disorder that could benefit from mapping Doxycycline as a treatment option. Here, we assess the use of Doxycycline as either monotherapy or adjunct therapy for epilepsy prophylaxis, with a particular emphasis on its intervention for nodding syndrome.

The primary objective of this study is to assess the safety and efficacy of Doxycycline for treating nodding syndrome. Also to comment on the likely use of Doxycycline as a form of adjunct therapy when paired with other antiepileptic drugs as a means to optimize the management efforts of nodding syndrome.

Our analysis included randomized controlled trials and observational studies which were sorted and assessed in accordance to PRISMA guidelines through a systematic search of the literature using all electronic databases, including PubMed, Google Scholar, Scopus, and Cochrane. The search terms included Doxycycline and nodding syndrome. The systematic set of extraction data were limited to studies that included a confirmed adolescent population exhibiting probable symptoms of nodding syndrome with Doxycycline as the primary intervention. Effect sizes will be measured with a random-effects model, and heterogeneity will be calculated with I² statistics.

Nine studies in total involving 1,120 subjects were analyzed, that included four randomized controlled trials (RCTs) assessing the effects of doxycycline monotherapy on 480 subjects, as well as five observational studies exploring the use of doxycycline with first-line anti-epileptic drugs (AEDs) on 640 subjects.

Seizure frequency reduction

Doxycycline administration on its own reduced seizure frequency by 30% relative to the placebo (relative risk [RR] = 0.70, 95% confidence interval [CI]= 0.60 to 0.85, p < .001), whereas, added to AEDs, reduced seizure frequency by 45% (RR = 0.552, 95% CI = = 0.42 to 0.73, p < 0.001; I² = 22%, considered low heterogeneity).

Lower severity of symptoms

The overall results suggest improvements in motor functions and cognitive assessments of -0.82 (standardized mean difference, 95% CI = -1.12 to -0.52, p < .001), which may indicate an improvement in motor symptoms.

AED add-on and impact on quality of life

Doxycycline with AED smear resulted in a reduction in seizure frequency of 45% (SMD = -0.68, 95% CI = -0.94 to -0.42, p < .001) and a statistically significant improvement in quality of life of approximately 25% (p < 0.01); effect estimates presented moderate heterogeneity (I² = 45%).

Doxycycline has potential for extended use since our findings support a safe and potentially beneficial intervention in nodding syndrome. Our study may serve as a useful guide for the use of antibiotics in other neuropathologies with inflammatory elements.

None Declared

Quitting alcohol use has been described as the main factor capable of modifying the prognosis of alcohol-related liver disease (ArLD). However, retention to the addiction treatment in these patients is low, and relapse in alcohol use is common. Misconceptions in the patients knowledge of the disease and the treatment impact retention. To improve retention, we have designed a blended intervention consisting in a presential brief intervention combined with a gamified webapp (MyWayUp). The intervention provides information regarding the liver disease and treatment, how to improve the prognosis, healthy lifestyles and how to achieve behavioural changes. The intervention was designed using a co-creation approach, and is based in well-stablished psychological principles (cognitive behavioural therapy, CBT; motivational interviewing, MI; psychoeducation; game-based learning).

The main objective is to explore the efficacy of the MyWayUp for improving retention to the addiction treatment in patients with ArLD at six months follow-up. As secondary objectives we explore: retention at 1 and three months, adherence to the treatment (attended visits from the total programmed), patterns of alcohol use and quality of life.

Prospective, randomised controlled trial, 6 months. Patients with ArLD onset would be invited to participate. If signed the informed consent, they would be randomised to the experimental or control condition. The experimental group would receive the brief intervention and given access to the webapp with a unique access code. Patients in the control group received treatment as usual, and after six months, if they had not adhered to the addiction unit, they would be invited to participate as experimental group. Both groups would be programmed the first visit with a psychiatrist, and followed at months 1, 3 and six after inclusion. The study was blinded for professionals and patients, and only one member in the research team would know the allocation group of each patient.

At baseline, sociodemographical variables were collected, as well as clinical data (presence of comorbidities), pattern of alcohol or other substances use (AUDIT; timeline follow back, TLFB), quality of life (EQ-5D-5L) and functionality (FAST). Several measure were taken at months 1, 3 and six: being active in the treatment at the assessment point (retention); adherence; alcohol and other substance use (TLFB) quality of life and functionality.

The final sample consisted of 82 patients, with a mean age of 55.3 (SD = 11.4). 38.2 % were women, and 53% of the participants were allocated to the experimental group.

Image 1:

Image 2:

MyWayUp has shown efficay in improving treatment retention and adherence as well as in improving abstinence rates.

None Declared

Antipsychotics’ adverse effects in combination with patients’ anosognosia, which is frequent among individuals with schizophrenia, lead to high rates of medication nonadherence. However, long-acting injectable (LAI) antipsychotics represent a veritable ally to the eyes of patients suffering from schizophrenia. Instead of the daily pill-taking required with oral antipsychotics, LAI antipsychotics are administered by injection at two- to four-week intervals, permitting patients to feel more independent, self-secure and free.

To explore the sociodemographic profile of patients receiving LAIs and to highlight the positive and the negative impact this treatment had on their health.

The study sample consisted of 44 patients followed-up in the Depot Outpatient Department of Papageorgiou General Hospital in Greece. The research was conducted between 2023 and March 2024. The sample was divided into subgroups according to gender, diagnoses - according to the International Classification of Diseases (ICD-10)-, and type of long-acting antipsychotic treatment. A bivariate analysis was performed to examine relationships between variables, such as: (a.) age; (b.) family status (c.) BMI; (d.) number of lifetime hospitalizations; (e.) lifetime suicide attempts.

63.6% of patients were men, 36.4% were females.

90.9% were diagnosed with Schizophrenia (F20).

31% were between 31 - 40 years old, while 26.2% were between 51 - 60 years old.

61.4% were unmarried, while 13.6% were married and 13.6% were divorced.

81.8% were unemployed/receiving welfare benefits.

68.2% lived with a relative.

56.8% claimed not suffering from physical diseases. However, when physical disorders were reported, they mainly included dyslipidaemia, diabetes and hypertension.

Based on their BMI, 37.2% were in the 2nd degree of obesity, 25.6% were in the 1st degree of obesity and 30.2% had normal weight.

47.7% were on olanzapine, 22.7% were on paliperidone and 11.4% were on haloperidol or aripiprazole.

The average value of years on LAI treatment was 3.5 years, with a minimum of 1 month and a maximum of 12 years.

Prior LAI treatment, the average value of hospitalizations was 3.5, with a minimum of 1 hospitalization and a maximum of 21 hospitalizations. After receiving treatment, 95.5% of patients were never hospitalized.

Prior LAI treatment, 88.6% of patients had no history of suicide attempts, while 11.4% had one or two suicide attempts. After receiving treatment, no participant had any suicide attempt.

Long-acting injectable antipsychotics help patients to live their lives outside of a psychiatric ward, by drastically diminishing the number of hospitalizations as well as the number of suicide attempts. But when it comes to their physical health, patients face many adverse effects, such as obesity. Clinicians must stay vigilant to ensure the quality of physical health of their patients.

None Declared

While an increase in mental disorders has been suggested, the role of societal changes, such as sociodemographic, vulnerability, or health-lifestyle factors, on this increase is scarce. This information is however crucial for health care policy and planning.

We examined trends in the 12-month prevalence of anxiety and mood disorders, their clinical profiles, and how sociodemographic, vulnerability, and health-lifestyle risk factors may have contributed to these trends.

We used data from 11,615 respondents (mean age= 43.5, 53.5% female) of the Netherlands Mental Health Survey and Incidence Study, examining the general population in 2007-2009 (NEMESIS-2, n= 6,646) and 2019-2021 (NEMESIS-3, n= 4,969). The Composite International Diagnostic Interview 3.0 was used to determine DSM-IV diagnoses. Logistic regression and interaction analyses were then conducted to assess the association between risk factors and the prevalence of anxiety and mood disorders, while also evaluating changes over time between the two cohorts.

The 12-month prevalence of all types of anxiety and mood disorders significantly increased from 2007–2009 to 2019–2022, with increases ranging from 56% to 125%. Clinical profiles of those with disorders were not milder in 2019-2022; there was greater mental health care use, a higher number of disorders, and an earlier age of onset. There was no consistent evidence that sociodemographic, vulnerability, or health-lifestyle risk factors became more prevalent over time or had a greater relative impact over time.

Our study showed a consistent increase in 12-month prevalence across all anxiety and mood disorders over the past decade. This rise in prevalence could not be explained by an increase in the absolute or relative impact of specific risk factors, nor were there significant differences in clinical profiles over time.

None Declared

A 64-year-old male with diabetes-related blindness was admitted with anxiety, low mood, and passive suicidal ideation. Despite no psychiatric history, he experienced visual hallucinations, which he recognized as “optical illusions.” A CT scan ruled out organic causes, and retinal detachment with irreversible vision loss was confirmed. Diagnosed with Charles Bonnet Syndrome (CBS), he developed delusional interpretations and auditory hallucinations. Initially treated with Venlafaxine 150 mg/day, his psychotic symptoms persisted until Risperidone was increased to 6 mg/day, which resolved the hallucinations. Lithium was then added, allowing a reduction in Risperidone without relapse.

This review, based on a case study, focuses on the challenges of treating Charles Bonnet Syndrome (CBS), early diagnosis, and the lack of clear diagnostic criteria. It explores the connection between CBS and visual loss, the emergence of psychotic symptoms, and the role of antipsychotics in managing them.

Literature was reviewed using the following keywords: (Charles Bonnet syndrome) AND (visual hallucinations OR hallucinations) AND (treatment OR management OR therapy OR pharmacotherapy). Databases such as PubMed were used to gather relevant studies.

There are several challenges in diagnosing and treating CBS. Underdiagnosis is common, leading to misdiagnoses such psychosis (Voit et al., 2021; Stojanov, 2016). Non-pharmacological approaches, including improving vision aids, have shown effectiveness in reducing hallucinations (Yacoub & Ferrucci, 2011; Pang, 2016).However, pharmacological treatments, including antipsychotics and SSRIs, have shown inconsistent results (Voit et al., 2021; Rojas & Gurnani, 2023). Differentiating CBS from psychiatric disorders is crucial, as patients typically retain awareness of the unreal nature of their hallucinations (Stojanov, 2016). Emerging research on CBS neurobiology suggests potential for future targeted therapies (Weil & Lees, 2021; Collerton et al., 2023).

Charles Bonnet Syndrome (CBS) is frequently underdiagnosed due to limited awareness and patient underreporting. Non-pharmacological approaches, such as improving vision and social support, help alleviate symptoms, though no standardized pharmacological treatments exist. This case underscores the importance of distinguishing CBS from psychiatric disorders, especially when psychotic features are present. A multidisciplinary approach, involving ophthalmologists, psychiatrists, and neurologists, is essential for effective management, as seen in this case. Early diagnosis and ongoing research are crucial for developing more targeted treatments for CBS.

None Declared

Jacobsen Syndrome (JS), or 11q Deletion Syndrome, is a rare genetic disorder affecting approximately 1 in 100,000 births, with a female-to-male ratio of 2:1 (Grossfeld et al. Am J Med Genet A. 2004; 129A(1):51-61). It is caused by a deletion on chromosome 11’s long arm, leading to diverse clinical features, affecting mainly the immune and cardiac systems (Dalm et al. J Clin Immunol. 2015; 35(8):761-8). Core neuropsychiatric symptoms include intellectual disability, psychomotor delays and distinctive physical traits. Recent reports highlighted attention deficits and autism-like characteristics (Akshoomoff et al. Genet Med. 2015; 17(2):143-8). Although previous studies identified varied cognitive profiles in JS, most focused on medical features, and a detailed psychiatric and cognitive characterisation is lacking.

This study aims to describe and analyse the psychiatric and cognitive profiles of individuals with JS as well as its associations, within a Spanish sample.

Twenty-nine participants aged 2 to 45 years were recruited from the Spanish association “11q España”. Psychiatric data were collected through interviews with parents and cross-referenced with medical reports, and behavioural symptoms were assessed using the Child Behavior Checklist (CBCL). Cognitive functioning was evaluated using Wechsler scales and the Merrill-Palmer-Revised scale.

The cohort’s average age was 12 years, with a female majority (68.9%). Psychiatric or neurodevelopmental comorbidities were present in over half (51.72%), with ADHD being the most common. According to the CBCL, 54.4% had internalising problems, and 54.5% had externalising problems. The average Intellectual Quotient (IQ) was 50.18, and the mean Developmental Quotient 36. When grouped by disability, 17.3% had borderline functioning, 17.3% mild, 21.7% moderate, 26% severe, and 17.3% profound ID. Higher IQ was associated with increased depression diagnoses and anxious/depressed symptoms.

This study provides a detailed neurocognitive profile of individuals with JS, confirming its heterogeneous presentation. Psychiatric comorbidities, especially ADHD, were common, and cognitive functioning ranged from borderline to profound ID, with no cases of normal cognition. Notably, participants with higher cognitive abilities were more prone to depression, highlighting the need for targeted mental health support tailored to individuals with JS.

None Declared

Social isolation refers to the lack of objective social contact and is one of the health risk factors. Previous studies have shown that social isolation is associated with several physical and mental disorders. However, the relationship between social isolation and schizophrenia remains unclear.

This study aimed to investigate whether there is a potentially causal association between social isolation and schizophrenia.

The UK Biobank (UKB) is a large population-based cohort study. In this study, social isolation was assessed using self-reported questionnaires. Participants were categorized into socially isolated and non-isolated groups based on the scores. We identified cases of schizophrenia through hospitalization records and death registrations in the UKB. Propensity score matching was used to reduce the influence of confounding factors. We estimated the hazard ratios (HRs) of social isolation to schizophrenia using Cox regression. In addition, we estimated the causal association between social isolation and schizophrenia by two-sample Mendelian randomization analysis. Genetic data for social isolation and schizophrenia were extracted from the UKB and the Psychiatric Genomics Consortium, respectively.

315 cases of schizophrenia were documented during a mean follow-up of 12.3 years. After adjusting for demographic, socioeconomic, and lifestyle factors, the risk of schizophrenia in the socially isolated group was 1.73 times higher than that in the non-socially isolated group (95% CI, 1.37-2.18). Results from two-sample Mendelian randomization analysis showed that participating in more other group activities was associated with a reduced risk of schizophrenia (OR, 0.49; 95% CI, 0.31-0.77).

Social isolation was potentially causally associated with an increased risk of schizophrenia. The results of this study emphasize the importance of reducing the risk of developing schizophrenia through initiatives to reduce social isolation and increase social activities.

None Declared

Schizophrenia is a mental disorder characterized by hallucinations, typically auditive ones, delusions, disorganized thinking and behavior, and flat or inappropiate affect. Symptoms develop gradually and usually begin during young adulthood and are never resolved completely. There is no objective diagnostic test; diagnosis is based on observed behavior, a holistic psychiatric history that includes the person’s reported experiences, and reports of others familiar with the patient.

• - Explore what schizophrenia is, its main characteristics and how it differs from other mental disorders.

• - Analyze how schizophrenia affects families and interpersonal relationships.

Middle-aged man who resides with his adoptive parents in a town near the municipal seat, unemployed and longitudinally with few social relationships and a lover of technology. He has attended psychiatric consultations on specific occasions and irregularly without a clear diagnosis. a single admission to a city psychiatric hospital for psychotic symptoms that subsided with medication. Since then, monitoring has been erratic and he has been given medication disguised by his parents during meals. In the last two weeks he has been especially distrustful and suspicious, even with his parents, so he has barely been able to sleep and does not eat properly for fear of being poisoned. He has confined himself to his room and refuses to be evaluated by a doctor and his anguish and emotional lability are increasing. For this reason, he is taken to the emergency room, where he is evaluated and it is determined that he is going through an episode with psychotic characteristics, which is why it is necessary, given the repercussion of the condition and the patient’s lack of cooperation, to be involuntarily hospitalized for treatment and stabilization.

During admission, he experiences episodes of intense agitation and serious behavioral alterations that require important pharmacological adjustments. In addition, work is done on awareness of the disease and acceptance of the diagnosis. Although he is initially reluctant to take any type of intervention, he progressively accepts taking medication and understands the nature of his problem, as well as the need to continue monitoring his disorder at an outpatient level. We were also able to provide psychoeducation to the family, thus achieving commitment and support on their part as well, since at first they were reluctant that their son could suffer from schizophrenia, for fear of the stigma and rejection that this could cause.

People with schizophrenia often face social stigmatization, which can lead to further marginalization, isolation and discrimination. This affects their emotional and mental well-being, contributing to a decrease in quality of life. Lack of adequate understanding of the disorder reinforces these myths and perpetuates discrimination.

None Declared

It is important to address the prevention and early detection of opioid addiction with a comprehensive approach. The collaboration and early attention are essential to mitigate the risks associated with opioid misuse. In this session we will review the myths associated with high risk of opioid addiction and how to address when it has been developed.

Some key strategies could be: Provide accurate and understandable information about the risks associated with opioid use, as well as the early signs of addiction. Consider alternative options for pain management, such as physical therapies, exercise, and medications non-opioids, before prescribing opioids. It is important balance pain relief with control of possible addiction risks. The appropriate and controlled indication of opioids is of vital importance to prevent and detect inappropriate use. Prescribe the lowest dose and duration shortest possible. It is important to visit frequent monitoring to detect signs of misuse and/or addiction.

None Declared

Alcohol withdrawal syndrome (AWS) is among the most severe components of alcohol dependence (AD). Severe AWS, especially complicated with seizures and delirium, was a common reason for medical complications and death. The introduction of benzodiazepines decreased but did not eliminate those risks. The definition of AWS evolved in different versions of Diagnostic and Statistical Manual for Mental Disorders (DSM) from having hand tremor plus one or more other symptoms in DSM-III-R to any two or more symptoms in DSM-IV, which was retained in the current version of DSM-5.

Comparing subgroups of individuals with AUD based on AWS symptoms profile to define phenotypes for investigation of biological underpinnings of AWS phenomenology and treatment response.

Treatment-seeking individuals diagnosed with DSM-IV alcohol dependence (AD; n=473; 35.5% females) were assessed with Psychiatric Research Interview for Substance and Mental Disorders (PRISM), Timeline Follow back (past 90 days) alcohol consumption, Penn Alcohol Craving Scale (PACS), Pittsburgh Sleep Quality Index (PSQI), Patient Health Questionnaire-9 (PHQ9), and General Anxiety Disorder-7 (GAD-7). Latent class analysis was used to classify subjects according to lifetime prevalence of AWS symptoms according to DSM-III-R or DSM-IV/5. Demographic and other clinical variables were compared among clusters by linear model ANOVA and chi-squared test.

Four clusters were identified: subjects with (1) no history of meeting any AWS criteria (n=50); (4) with complete number of AWS symptoms, meeting both DSM definitions (n=259); and two clusters of subjects with smaller number of AWS symptoms: (3) those meeting only DSM-IV/5 criteria (n=94) and (2) those also meeting DSM-III-R criteria (n=70). Compared to cluster 2, the Cluster 3 members had higher frequency of anxiety, insomnia, and restlessness during withdrawal. The clusters also differed in the total number of drinks (p=0.021), average drinks per drinking days (p=0.013), history of anxiety disorder (p=0.006), substance-induced depression (p=0.019), and higher scores of PSQI (p<0.001), PHQ9 (p<0.001), and GAD-7 (p<0.001) with a relative increase in frequency between clusters as follows 1<2<3<4. Group 4 also had the highest percentages of subjects with history of seizure, delirium or hallucinations.

Different definitions of AWS capture clusters of AD patients with different symptomatology, comorbidity and consumption patterns. Understanding of biological underpinnings behind those differences may guide improvement in personalized treatment selection.

None Declared

Delusional parasitosis is a psychotic disorder where individuals firmly believe they are infested with parasites despite no medical evidence. It can be primary or secondary, the latter being a symptom of other medical conditions like neurological diseases. Effective management requires collaboration between psychiatry and other specialties.

The evaluation of each patient with an interdisciplinary team increases adherence to treatment in patients with cancer and psychiatric illness.

Clinical history, complementary studies, and review of the literature on the case of a 66-year-old woman subjected to multiple dermatological treatments due to a sensation of body infestation. History of type 2 diabetes and diabetic neuropathy since 2021. In 2022, she was diagnosed with stage IIIA luminal B breast cancer and treated with surgery, chemotherapy, and radiotherapy. She is currently on adjuvant treatment with Anastrozole. The oncologist referred her due to the presence of psychotic symptoms. The General Health Questionnaire (GHQ-28), Functional Assessment of Cancer Therapy—General (FACT-G), and Positive and Negative Syndrome Scale (PANSS) were applied.

The patient presents with a psychotic disorder secondary to vascular pathology, manifested by delusions of infestation and sudden-onset hypodermic tactile hallucinations. Test results show a GHQ-28 score of 10/84, FACT score of 24/108, and PANSS score of 49 points. Although denying affective symptoms, anxiety, or cognitive impairment, neurological findings indicate decreased brain parenchyma, suggesting small vessel disease. Treatment includes Risperidone 1 mg once daily, along with therapeutic interventions such as psychoeducation and continued multidisciplinary monitoring by neurology for comprehensive disease management.

Evaluating psychotic symptoms requires assessing organic and non-organic factors. Neuroimaging aids diagnosing delusional parasitosis, improving treatment through interdisciplinary collaboration.

None Declared

Anorexia Nervosa (AN) is a complex psychiatric disorder often understood through a Western lens. This study explores AN in the Cambodian context, where the condition is not traditionally recognized, to uncover cultural and transcultural aspects of the illness.

This research aims to conduct an in-depth phenomenological exploration of AN cases in Cambodia, documenting the lived experiences of individuals and identifying cultural or transcultural elements within the universal description of AN.

Employing a qualitative research approach grounded in phenomenology, this study will involve in-depth interviews with Cambodian individuals experiencing AN. The data will be analyzed using both descriptive and interpretive phenomenological methods, ensuring the bracketing of researcher bias and fostering co-creation of interpretations.

Expected outcomes include a comprehensive phenomenological account of AN in Cambodia, shedding light on the lived experiences of individuals and potentially revealing unique cultural dimensions of the disorder. The study will contribute to the understanding of AN from a transcultural perspective, highlighting both universal and culturally specific aspects.

This research is anticipated to provide valuable insights into the phenomenology of AN in a non-Western context. The findings may have implications for clinical practice, research, and cross-cultural understanding of AN, emphasizing the importance of patient-centered approaches and the exploration of lived experiences in psychopathology.

S. Bora Grant / Research support from: International Exchange Award from the Renewing Phenomenological Psychopathology funded by the Wellcome Trust, R. Ngin: None Declared, S. Vilhem: None Declared

Digital phenotyping offers a valuable method for predicting and preventing nonsuicidal self-injury (NSSI) in daily life by providing objective, ecologically valid measurements at multiple time points. This approach quantifies an individual’s phenotype by capturing self-injury-related markers such as mood, step counts, and heart rate.

The aim of this study is to identify real-time predictors and to elucidate the dynamic trajectory of NSSI in individuals.

This study targets individuals in their 20s residing in South Korea who engaged NSSI on five or more days during the past year, and a total of 56 participants were included in the current study. Once participants were enrolled, active (e.g., ecological momentary assessment) and passive (e.g., heart rate, step count) data were collected via a smartphone app and wrist-worn wearables for 14 days. Initially, a random forest algorithm was employed to assess the relative importance of passive and active data in predicting NSSI thoughts. Subsequently, a multilevel logistic regression model was used to capture variability at both the within-person and between-person levels.

After inputting passive data into the random forest algorithm, the model demonstrated an accuracy of 0.619. Among the variables, walking stride had the highest importance score at 0.28, followed by heart rate (0.18) and heart rate variability (0.17). Subsequently, when analyzing the random forest algorithm with active variables, the model’s accuracy was found to be 0.666. In this case, anger toward others had the highest importance score at 0.26, followed by depression (0.22) and anger toward oneself (0.19). In a separate analysis using multilevel logistic regression models for each passive variable, none of the variables produced significant results in either the fixed or random effects analyses. However, when active variables were entered into separate multilevel logistic regression models, all emotional variables yielded significant results in the fixed effects analysis: depression (0.746, p < .001), anxiety (0.521, p < .001), anger toward oneself (0.475, p < .001), anger toward others (0.403, p < .001), loneliness (0.329, p < .001), and shame (0.557, p < .05). In contrast, none of the variables showed significant results in the random effects analysis.

The findings from this study could offer insights into novel mechanisms underlying the occurrence of self-injurious thoughts and their prediction in daily life. Additionally, this advanced approach may help identify optimal strategies for NSSI prevention and enable the delivery of personalized, real-time interventions.

None Declared

Despite rigorous evidence of the benefits, costs and savings and mentions in treatment guidance, cognitive remediation access is still sparse. Providers are often confused by disagreements about the strength of the benefits evidence, some think it is a game not a treatment and others do not consider that cognition should be a treatment target. These are all issues that were present in the literature at least ten years ago.

To identify the steps to widespread implementation of this beneficial intervention

Drawing on the literature and data from a large UK adaptive randomised control trial, we describe three: (i) the barriers and facilitators for the implementation into first episode services, (ii) cost effectiveness and (iii) training rollout and competency.

(i) Clinicians need to understand the relevance of cognition and be aware of effective interventions, (ii) Despite evidence of efficacy a therapist seems important for engagement and leads to cost effective therapy and (iii) online therapy can improve competencies for delivering cognitive therapy and but commitment to completing therapy is related to management commitment.

All the implementation issues can be overcome but we still need to understand the non-specific effects of cognitive remediation as well as the specific if we are to provide a formulation-based approach. Clinicians need to know that cognitive remediation is not “brain training” but is a holistic therapy that involves an active therapist providing motivation support, and who helps to mitigate the impact of cognitive difficulties through metacognition to develop awareness of cognitive approaches to problems.

T. Wykes Grant / Research support from: NIHR grant 2.2m